CSTL
CASTLE BIOSCIENCES INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$35.34
−3.92%Sep 15, 2026, 11:00 UTC
Castle Biosciences announced the publication of a decision modeling study showing its TissueCypher Barrett's Esophagus test improves risk-aligned management for patients with Barrett's esophagus.
Source:Sep 9, 2026, 20:30 UTC
Castle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma.
Source:Jul 30, 2026, 22:06 UTC
Castle Biosciences reported second-quarter 2026 revenue of $103.5 million, up 20% year-over-year.
Jul 14, 2026, 20:30 UTC
Castle Biosciences received assay approval from the New York State Department of Health for its AdvanceAD-Tx test.
Source:Jun 16, 2026, 11:00 UTC
Castle Biosciences' TissueCypher Barrett's Esophagus Test surpassed 100,000 clinical test orders.